[{"id":"8b6df141-7b64-4f9b-89f3-9e3e39a78d70","acronym":"NCI-2017-00831","url":"https://clinicaltrials.gov/study/NCT03066206","created_at":"2021-01-17T17:10:50.278Z","updated_at":"2024-07-02T16:35:01.092Z","phase":"Phase 2","brief_title":"Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC","source_id_and_acronym":"NCT03066206 - NCI-2017-00831","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 V777L • EGFR exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 19 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pozenveo (poziotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"}]